The Role Of Alpha-haemoglobin Stabilising Protein In Haemoglobin Production And As A Therapeutic For Thalassaemia.
Funder
National Health and Medical Research Council
Funding Amount
$320,936.00
Summary
Thalassaemias are the most common hereditary diseases effecting the production of red blood cells. The underlying cause of disease is a failure to produce normal quantities of haemoglobin (Hb; the essential oxygen-carrying molecule in blood), resulting in severe anaemia. We have discovered a new protein with an important role in Hb production. We will elucidate the function of this protein in red blood cells and investigate novel treatments for thalssaemia disease.
The Role Of Huntingtin Misfolding And Oligomerization In Huntingtons Disease
Funder
National Health and Medical Research Council
Funding Amount
$474,329.00
Summary
Mutations in the huntingtin gene cause Huntington's disease by making the gene product aggregate together into non-normal and different sized polymers. However, it is not understood how this process causes cells to die, largely because we don't understand how the abnormal forms accumulate in cells over time. We will examine where in cells the abnormal shapes accumulate and how they cause toxicity. This research will identify critically-needed therapeutic targets against Huntington's disease.
Great advances have been made in pharmaceutical design and discovery over the last 50 years. While drugs have traditionally been discovered using random screening of natural product libraries and chemical databases, new technologies in protein chemistry, structural and molecular biology have been adopted in efforts to speed the drug design process and increase its hit rate. In addition, our rapidly increasing knowledge of the molecular causes of many diseases provides us with many opportunities ....Great advances have been made in pharmaceutical design and discovery over the last 50 years. While drugs have traditionally been discovered using random screening of natural product libraries and chemical databases, new technologies in protein chemistry, structural and molecular biology have been adopted in efforts to speed the drug design process and increase its hit rate. In addition, our rapidly increasing knowledge of the molecular causes of many diseases provides us with many opportunities to develop therapeutics directed towards known molecular targets. Nevertheless, despite these advances, problems such as drug resistance and toxic side effects that compromise drug efficacy make it clear that there is a need for new classes of drugs with different modes of action. Because of their favourable properties, small-molecule drugs comprise by far the largest class of currently available therapeutics. However, in many cases, a drug derived from a protein may be preferable. The development of protein-based drugs is a youthful and rapidly expanding area of biotechnology, but to date, most studies have focused on targeting pathological events that occur on the outside of cells. We propose to use a combination of methods from molecular and structural biology, together with recently developed high-throughput screening techniques, to develop a generic protein drug scaffold that can be used as a template to develop therapeutics against a wide range of inappropriate interactions that may occur between molecules within cells.Read moreRead less